细胞毒性T细胞
免疫系统
癌症
癌症研究
类有机物
癌症免疫疗法
免疫疗法
免疫学
CTL公司*
CD8型
树突状细胞
医学
抗原
癌细胞
生物
细胞生物学
内科学
体外
生物化学
作者
Jayati Chakrabarti,Vivien Koh,Jimmy Bok Yan So,Wei Peng Yong,Yana Zavros
摘要
Tumors expressing programmed cell death-ligand 1 (PD-L1) interact with programmed cell death protein 1 (PD-1) on CD8+ cytotoxic T lymphocytes (CTLs) to evade immune surveillance leading to the inhibition of CTL proliferation, survival, and effector function, and subsequently cancer persistence. Approximately 40% of gastric cancers express PD-L1, yet the response rate to immunotherapy is only 30%. We present the use of human-derived autologous gastric cancer organoid/immune cell co-culture as a preclinical model that may predict the efficacy of targeted therapies to improve the outcome of cancer patients. Although cancer organoid co-cultures with immune cells have been reported, this co-culture approach uses tumor antigen to pulse the antigen-presenting dendritic cells. Dendritic cells (DCs) are then cultured with the patient's CD8+ T cells to expand the cytolytic activity and proliferation of these T lymphocytes before co-culture. In addition, the differentiation and immunosuppressive function of myeloid-derived suppressor cells (MDSCs) in culture are investigated within this co-culture system. This organoid approach may be of broad interest and appropriate to predict the efficacy of therapy and patient outcome in other cancers, including pancreatic cancer.
科研通智能强力驱动
Strongly Powered by AbleSci AI